Purple Biotech Ownership
| PPBT Stock | USD 2.19 0.35 13.78% |
Shares in Circulation | First Issued 2014-09-30 | Previous Quarter 27.5 M | Current Value 173.3 K | Avarage Shares Outstanding 33.5 M | Quarterly Volatility 57.3 M |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Purple |
Purple Stock Ownership Analysis
The company has price-to-book ratio of 0.14. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Purple Biotech recorded earning per share (EPS) of 81.0. The entity last dividend was issued on the 21st of August 2020. The firm had 1:20 split on the 17th of September 2024. Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug for cancer patients in the United States. The company was formerly known as Kitov Pharma Ltd and changed its name to Purple Biotech Ltd. in December 2020. Purple Biotech operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 19 people. To find out more about Purple Biotech contact the company at 972 3 933 3121 or learn more at https://purple-biotech.com.Besides selling stocks to institutional investors, Purple Biotech also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Purple Biotech's stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Purple Biotech's strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Purple Biotech Quarterly Liabilities And Stockholders Equity |
|
Roughly 3.0% of Purple Biotech are currently held by insiders. Unlike Purple Biotech's institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Purple Biotech's private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Purple Biotech's insider trades
Purple Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Purple Biotech is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Purple Biotech backward and forwards among themselves. Purple Biotech's institutional investor refers to the entity that pools money to purchase Purple Biotech's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Group One Trading, Lp | 2024-06-30 | 400 | Rhumbline Advisers | 2024-06-30 | 16.0 | Global Retirement Partners, Llc. | 2024-09-30 | 16.0 | Sound Income Strategies | 2024-09-30 | 0.0 | Venture Visionary Partners Llc | 2024-09-30 | 0.0 | Millennium Management Llc | 2024-06-30 | 0.0 | Kingswood Wealth Advisors Llc | 2024-09-30 | 0.0 | North Star Investment Management Corp | 2024-09-30 | 0.0 | Wealth Advisors Of Iowa, Llc | 2024-09-30 | 0.0 | Armistice Capital, Llc | 2024-06-30 | 1.4 M | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 406 K |
Purple Biotech Outstanding Bonds
Purple Biotech issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Purple Biotech uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Purple bonds can be classified according to their maturity, which is the date when Purple Biotech has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View | |
| MGM Resorts International Corp BondUS552953CD18 | View | |
| AerCap Global Aviation Corp BondUS00773HAA59 | View |
Purple Biotech Corporate Filings
6K | 15th of November 2024 A report filed by foreign private issuers with SEC. A foreign private issuer is a non-U.S. company with securities traded on U.S. exchanges. | ViewVerify |
13A | 14th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
| 31st of July 2024 Other Reports | ViewVerify | |
| 22nd of July 2024 Other Reports | ViewVerify |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Purple Stock Analysis
When running Purple Biotech's price analysis, check to measure Purple Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Purple Biotech is operating at the current time. Most of Purple Biotech's value examination focuses on studying past and present price action to predict the probability of Purple Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Purple Biotech's price. Additionally, you may evaluate how the addition of Purple Biotech to your portfolios can decrease your overall portfolio volatility.